Targeted market survey of undeclared sildenafil in high-risk sexual enhancement supplements marketed in Hungary

Abstract Undeclared phosphodiesterase type 5 (PDE5) inhibitors in dietary supplements marketed as natural sexual enhancers remain a consumer protection and food safety concern. This article investigates the occurrence of undeclared sildenafil in 12 high-risk sexual enhancement supplements marketed in Hungary as part of a targeted market survey. Sildenafil was screened using an in-house HPLC–UV/DAD method. Seven of the 12 products showed signals consistent with sildenafil, with contents ranging from 0.22 to 122 mg per unit. Two products contained amounts exceeding the maximum recommended dose of 100 mg, while 3 additional products contained amounts approximately equivalent to the 50 mg reference dose. These findings demonstrate that undeclared pharmaceutical adulteration remains present in selected high-risk sexual enhancement supplements available on the Hungarian market. Continued risk-based post-market control and regulatory monitoring are warranted to reduce consumer exposure to undeclared pharmacologically active substances.